Fabulous post, Jesse2233, and very interesting news! Thanks so much for being such a great "journalist" for the forum. Glad Dr Chia was able to confirm that oxymatrine may help your recovery, and was able to put your mind at rest regarding your heart symptoms.
Sees disproportionate amount of white and especially Jewish people with chronic enteroviruses, fewer Asians.
Intriguing! Perhaps we need to start looking at Ashkenazi genetic SNP polymorphisms, and figure out why this might be.
Equilibrant tends to help 50% (out of the 1,000 he's given it to), 30% are major responders (like night / day, bedridden to back to work in 3-6 months). 66% effectiveness against coxsackie B. Better in younger patients (considered 30 young), better for men, people early into the illness, and African Americans / Hispanics.
I can certainly accept that oxymatrine will help 50% of enterovirus-associated ME/CFS patients overall, but I have always found it strange that as far as I am aware, we have never had anyone on this forum who had this bedridden to back-to-work major response from oxymatrine. If 30% of Dr Chia's enterovirus ME/CFS patients are achieving this, you'd think we would have had quite a few on this forum with similar responses, but I have not seen even one. So that is something of a mystery.
Nancy Klimas has given Equilibrant to 300 patients with similar success percentages.
I did not know that. Very interesting.
Mold and other Th2 triggers can lessen the effect of the Oxymatrine
That's a hypothesis that I was exploring a while ago in this thread
. My general thoughts were that exposure to any factors that promote Th2 might both act to prevent viral clearance, as well as thwart any Th1 boosters such as oxymatrine or inosine.
Take Equilibrant for at least 1 year even if it's working to prevent relapse
quotes Dr Chia saying that for men, once they get better on oxymatrine, they can discontinue this medication after 6 months. But women usually have to continue taking it (presumably indefinitely), because when they stop, they usually relapse within the next month.
IV matrine is even more effective but he can't give it here (didn't explain why). Studies in China (written in Chinese) show 2 months IV matrine has 97% effectiveness for chronic coxsackie B myocarditis vs 0% in placebo
Fascinating! I did come across some Chinese injectable oxymatrine (rather than matrine) products for sale online a few years ago. I am going to search the Chinese market again to try to find some matrine injectables for sale.
Yes a cure. There are two new extremely potent CBV4 antivirals coming out, one from Belgium. Said the name was a long number.
the researchers said it should work in chronic viral infections because it blocks replication of the RNA.
Wow! And double wow! I'd love to know what those two new drugs are. If you look at the very bottom of my enterovirus antivirals post
, you will see a list of enterovirus antiviral drugs still in the research and development pipeline (with code names like BTA-798, TTP 8307, etc); the two new CVB4 drugs might be in that list. Maybe when you get a chance to listen to your recording of your appointment, you will be able to get the name.
Ampligen is a bad drug. The studies were bad. Maybe helps 10% of people
LDN is ok. Can help with sleep and pain, helps 10-20%. Should be safe to take alongside Equilibrant.
IVIG helps 20-25% of people.
Interesting that Dr Chia finds IVIG can help a reasonable percentage of patients. He did say in the 2009 Invest in ME Conference video that the problem with IVIG is mainly that insurance companies will not pay for it.
Rituximab is interesting. He's in contact with Fluge and thinks well of him. Thinks it helps those with an autoimmune condition but not CFS with he attributes to a smoldering virus.
Said 40% of the people in the 30 person trial had a relative with an autoimmune condition vs 5% normally.
He thinks their positive results are also because of the Norwegian population's homogeneity and high incidence of autoimmune issues.
Very interesting. @Jonathan Edwards
might want to comment.
If the cohort in the 30 person Fluge and Mella phase II rituximab trial contained an inordinate number of Norwegian people that are prone to autoimmunity, that would help explain the high success rate, but it might also entail that rituximab might not work as well for other ME/CFS patient cohorts in different countries.
That might explain why on these forums, the response rate of those who posted their rituximab results has not been very good. Out of the 14 people on this forum who I saw posted their results, only 1 person had a very good response, another 1 or 2 had moderate to mild responses, and the rest did not respond at all to rituximab.
That said, the Kolibri Medical hospital in Norway are getting a good success rate from rituximab (they report
⅓ cured, ⅓ improved, ⅓ no response), but again they may be treating mostly Norwegian ME/CFS patients.
in this post
said that Dr Kaufman of the Open Medicine Institute in the US told him the OMI's rituximab success rate for ME/CFS was similar to the Fluge and Mella phase II rituximab trial's. So that is some indication that rituximab does work for non-Norwegian cohorts.